title: Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding.
abstract: Tranexamic acid, a synthetic lysine derivative, is an antifibrinolytic drug that prevents the breakdown of fibrin by competitively blocking binding sites of plasminogen. Tranexamic acid is often considered a first-line treatment for the management of heavy menstrual bleeding (HMB). A new oral formulation of tranexamic acid provides a nonhormonal HMB therapy that is safe, effective and well tolerated; is administered only during menstruation; addresses the excessive fibrinolysis implicated in many cases of HMB; and improves women's health-related quality of life by reducing limitations on physical, social and leisure activities. This article provides a summary of the clinical development, therapeutic efficacy and tolerability profile of this novel formulation of tranexamic acid for the treatment of HMB.
authors.affiliation: Rochester General Hospital, 1425 Portland Ave, Rochester, NY 14621, USA. andrealukes@cwrwc.com
authors.forename: Andrea S
authors.initials: AS
authors.lastname: Lukes
authors.forename: Peter A
authors.initials: PA
authors.lastname: Kouides
authors.forename: Keith A
authors.initials: KA
authors.lastname: Moore
mesh_terms: D000933:Antifibrinolytic Agents / Q000494:pharmacology* / Q000592:standards; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008595:Menorrhagia / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D014148:Tranexamic Acid / Q000494:pharmacology* / Q000592:standards; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid